The Oxford group has already begun their phase 3 trials on thousands of people in the UK, Brazil, and South Africa. In August it will begin similar trials on 30,000 people in the US.

📬 Sign up for the Daily Brief

Our free, fast, and fun briefing on the global economy, delivered every weekday morning.